Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV
Shumway, David
Dynport Vaccine Company, LLC, Frederick, MD, United States
Search 14 grants from David Shumway
Search grants from Dynport Vaccine Company, LLC
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Implementation Laboratory
Influence of Aging on Mitochondrial Gene Expression Following Trauma-Hemorrhage
Translational Research on Eating Disorders
Mechanisms of G2/M cell cycle checkpoint controls
Excitation-Contraction Coupling in Crustacean Muscle
Recently added grants:
Obesity dysregulates immune and metabolic status in asthma and alters infection susceptibility.
Therapeutic Antibody for RSV IIB
Therapeutic activation of AMPK for the aging right heart
Mechanisms of IL-33 secretion in allergic diseases
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
272201500005I-1-27200003-1
Application #
9430351
Study Section
Project Start
2016-08-23
Project End
2017-04-30
Budget Start
Budget End
Support Year
Fiscal Year
2017
Total Cost
Indirect Cost
Institution
Name
Dynport Vaccine Company, LLC
Department
Type
DUNS #
014130053
City
Frederick
State
MD
Country
United States
Zip Code
21702
Related projects
Comments
Be the first to comment on David Shumway's grant
